The absence of institutional selling and presence of coordinated accumulation — especially UBS's near-tripling of shares — suggests growing confidence among large financial players. Traders should monitor for follow-on buying, upcoming clinical trial data, or analyst upgrades as potential catalysts. However, given that all buyers are passive mega-banks, this may reflect index rebalancing rather than active conviction.
Executive Summary
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — increased their positions in ImmunityBio (IBRX) during Q4 2024, with UBS doubling its stake and the group collectively adding $4.4M in net new value. Despite a minor valuation dip at Wells Fargo, all moves reflect strong accumulation, concentrated among large financial institutions. This coordinated buying suggests growing institutional confidence in IBRX, potentially signaling sector interest in the company's immuno-oncology pipeline.
Key Financial Metrics
Institutional Positions
Net institutional flow: $4.4M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | ADD | +78.3% | $10.3M | $1.9M |
| Wells Fargo | ADD | +30.4% | $355.0K | -$40.5K |
| UBS | DOUBLED | +290.6% | $4.1M | $2.6M |
Key Facts
- Morgan Stanley increased holdings by 1.76M shares, adding $1.9M in value (total position now $10.3M)
- UBS more than doubled its stake, adding 1.18M shares and increasing position value by $2.6M to $4.1M
- Wells Fargo added 32.3K shares despite a slight drop in total position value from $395K to $355K, likely due to share price movement
- No institutional selling observed in this cluster; 3 buyers, 0 sellers
Financial Impact
3 institutions accumulated $4.4M in net new positions during Q4 2024, increasing total holdings from $10.3M to $14.7M
Risk Factors
- All buyers are passive institutions (mega_passive), reducing the strength of the signal compared to active manager conviction
- Wells Fargo's position value declined slightly despite share increase, indicating possible price pressure or lagging performance in the quarter
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-IBRX-2024-Q4 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $6.95 $7.87 | ▲ +13.24% | ▲ +14.48% | — |
Jul 6, 2026 12w ago | Insider Cluster | $8.91 $7.17 | ▼ −19.53% | ▼ −18.96% | — |
Jul 1, 2026 13w ago | Insider Cluster | $9.20 $6.83 | ▼ −25.76% | ▼ −23.58% | — |
May 18, 2026 19w ago | 8-K | $7.76 $6.99 | ▼ −9.92% | ▼ −10.91% | — |
Apr 9, 2026 25w ago | 8-K | $7.48 $8.38 | ▲ +12.03% | ▲ +4.46% | — |
Apr 6, 2026 25w ago | 8-K | $7.08 $7.43 | ▲ +4.94% | ▼ −4.04% | — |
Feb 28, 2026 30w ago | Institutional Cluster | $10.44 $6.66 | ▼ −36.21% | ▼ −28.27% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access